Ocular Therapeutix/OCUL

$5.06

-3.07%
-
1D1W1MYTD1YMAX

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Ticker

OCUL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Pravin Dugel

Employees

267

Headquarters

Bedford, United States

OCUL Metrics

BasicAdvanced
$775.84M
Market cap
-
P/E ratio
-$0.99
EPS
1.47
Beta
-
Dividend rate
$775.84M
1.46875
$11.31
$2.00
2.26M
6.655
6.589
82.217
82.217
-6.57%
-40.23%
-127.64%
-48.19%
13.275
6.585
8.513
13.5%
-7.57%
49.75%

What the Analysts think about OCUL

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
206.32% upside
High $24.00
Low $11.00
$5.06
Current price
$15.50
Average price target

OCUL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-197.29% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$14.8M
-1.33%
Net income
$-29.2M
5,740%
Profit margin
-197.29%
5,824.62%

OCUL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 15.13%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.39
-$0.26
-$0.01
-$0.35
-
Expected
-$0.26
-$0.30
-$0.29
-$0.30
-$0.19
Surprise
48.01%
-13.91%
-96.52%
15.13%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Ocular Therapeutix stock?

Ocular Therapeutix (OCUL) has a market cap of $775.84M as of April 23, 2024.

What is the P/E ratio for Ocular Therapeutix stock?

The price to earnings (P/E) ratio for Ocular Therapeutix (OCUL) stock is 0 as of April 23, 2024.

Does Ocular Therapeutix stock pay dividends?

No, Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Ocular Therapeutix dividend payment date?

Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders.

What is the beta indicator for Ocular Therapeutix?

Ocular Therapeutix (OCUL) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Ocular Therapeutix stock price target?

The target price for Ocular Therapeutix (OCUL) stock is $15.5, which is 205.72% above the current price of $5.07. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Ocular Therapeutix stock

Buy or sell Ocular Therapeutix stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing